Literature DB >> 15285710

A call for replicating vector prime-protein boost strategies in HIV vaccine design.

Nina V Malkevitch1, Marjorie Robert-Guroff.   

Abstract

A key challenge to HIV vaccine development is the integration of HIV proviral DNA into the host genome upon infection. Therefore, an optimal vaccine should block infection within hours of viral exposure, providing 'sterilizing immunity' at mucosal sites and in blood via potent, broadly reactive antibody to the HIV envelope glycoprotein. This is difficult due to the envelope's conformational complexity and sequence diversity. Antibodies that do not completely prevent infection nevertheless could reduce the viral infectious burden, allowing strong cellular immunity to control viremia, delay disease progression and prevent viral transmission, while also providing help for T- and B-cell responses. Rapidly responsive, potent, persistent immunity might best be achieved using prime-boost strategies incorporating a replicating vector and an optimally designed envelope subunit.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285710     DOI: 10.1586/14760584.3.4.s105

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  15 in total

1.  Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Authors:  Ruth H Florese; Roger W Wiseman; David Venzon; Julie A Karl; Thorsten Demberg; Kay Larsen; Leon Flanary; V S Kalyanaraman; Ranajit Pal; Fausto Titti; L Jean Patterson; Megan J Heath; David H O'Connor; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

Review 2.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

3.  Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Authors:  Rachmat Hidajat; Seraphin Kuate; David Venzon; Vaniambadi Kalyanaraman; Irene Kalisz; James Treece; Ying Lian; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2010-04-09       Impact factor: 3.641

4.  The Current State of Vaccine Development for Ocular HSV-1 Infection.

Authors:  D J Royer; A Cohen; Djj Carr
Journal:  Expert Rev Ophthalmol       Date:  2015-04-01

Review 5.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

6.  Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Authors:  Ruth H Florese; Thorsten Demberg; Peng Xiao; LaRene Kuller; Kay Larsen; L Ebonita Summers; David Venzon; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

Review 7.  Intestinal M cells: the fallible sentinels?

Authors:  Harvey Miller; Jianbing Zhang; Rhonda Kuolee; Girishchandra B Patel; Wangxue Chen
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

8.  Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Authors:  Rachmat Hidajat; Peng Xiao; Qifeng Zhou; David Venzon; L Ebonita Summers; Vaniambadi S Kalyanaraman; David C Montefiori; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

Review 9.  Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

10.  Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.

Authors:  Thorsten Demberg; Jean D Boyer; Nina Malkevich; L Jean Patterson; David Venzon; Ebonita L Summers; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; David B Weiner; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.